Host: Carol Wysham, MD 


  Guest: Rodica Pop-Busui, MD, PhD 



  
    Type 2 diabetes can be reflected in a patient's oral health, but can we say the same for patients with type 1 diabetes? Here to dive into that question and to share her latest findings in oral health in patients with type 1 diabetes is Dr. Rodica Pop-Busui, a Larry D. Soderquist Professor of Diabetes and Vice-chair for Clinical Research in the Department of Internal Medicine and also the Director of Clinical Research, Mentoring and Development of M-Diabetes at the University of Michigan.

Evaluating the Importance of Oral Health in T1D

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease.
Because when it comes to diabetes, glucose control is just the beginning.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

Guest: Elena Toschi, MD 



  
    Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn more, join Dr. Elena Toschi, Director of the Young Adult Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.

Uncovering the Prevalence of Type 1 Diabetes in Older Adults

Host: John Buse, MD, PhD 


  Guest: Kim Boggess, MD 



  
    The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these patients? Join Dr. John Buse as he talks about the MOMPOD Trial with lead author, Dr. Kim Boggess, Professor of Maternal Fetal Medicine at the University of North Carolina at Chapel Hill. 

Concentrating on the MOMPOD Trial for Metformin Plus Insulin

Guest: R. Paul Wadwa, M.D. 



  
    Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their blood sugars. However, a recent study identified that hybrid closed-loop technology could help give children with type 1 diabetes the best outcomes and quality of life. To learn more, tune in with Dr. Paul Wadwa, Professor of Pediatrics and the Medical Director of the Pediatric Clinic at the Barbara Davis Center for Diabetes at University of Colorado Anschutz Medical Campus.

Utilizing Hybrid Closed-Loop Technology for T1D Pediatric Patients

Host: Carol Wysham, MD 


  Guest: A. Michael Lincoff, MD 



  
    Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.

Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients

Host: John Buse, MD, PhD 


  Guest: Louis J. Aronne, MD, FTOS 



  
    In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.

Evaluating the Importance of Oral Health in T1D

Download our free app to listen on your phone